Circulating Vesicular-bound HLA-G as Noninvasive Predictive Biomarker of CLAD After Lung Transplantation

Olivier Brugière,Dora Dreyfuss,Ronan Guilet,Sophie Rong,Sandrine Hirschi,Benjamin Renaud-Picard,Martine Reynaud-Gaubert,Benjamin Coiffard,Vincent Bunel,Jonathan Messika,Xavier Demant,Jérôme Le Pavec,Gaelle Dauriat,Christel Saint Raymond,Loic Falque,Jean-Francois Mornex,Adrien Tissot,David Lair,Aurelie Le Borgne Krams,Veronique Bousseau,Antoine Magnan,Clément Picard,Antoine Roux,Matthieu Glorion,Maryvonick Carmagnat,Florence Gazeau,Kelly Aubertin,Edgardo Carosella,Alexandre Vallée,Cecile Landais,Nathalie Rouas-Freiss,Joel LeMaoult,COLT Consortium,J Jougon,J Macey,H Rozé,E Blanchard,C Dromer,X Demant,M Ruiz-Patino,M Vander Kuylen,Y Sokolow,C C Stefanidis,I Huybrechts,L Perrin,L Van Obberghe,F Taccone,D Grimaldi,I Etienne,C Knoop,J L Vachiéry,C Dewachter,A Roussoulières,M Hites,F Jacobs,L Collignon,A-M Salumu,A Hemelsoet,P Bedouch,A Briault Falque,Q Perrin,C Pison,C Saint Raymond,S Chacaroun,Y Gioria,V Cottin,J-F Mornex,C Merveilleux du Vignaux,E Chatron,C Barnel,B Vaz,F Tronc,G Drevet,J-M Maury,R Grima,P Portranaurelie,M Reignier,N Carlier,V Boussaud,F Le Pimpec-Barthes,A Bel,P Achouh,R Guillemain,G Brioude,X B D'Journo,P Thomas,D Trousse,M Leone,F Bregeon,B Coltey,N Dufeu,A Nieves,H Dutau,J Y Gaubert,Ch Picard,M Reynaud-Gaubert,D Boulate,A Basire,J Bermudez,A Charvet,B Coiffard,F Daviet,J L Delamarre,J M Forel,A Fourdrain,C Gautier,S Giusiano,C Guervilly,P Habert,S Hraiech,A Labarrière,P Mora,P Pedini,P Lacoste,C Perigaud,J C Roussel,T Senage,A Mugniot,I Danner,A Tissot,C Bry,M Penhouet,E Eschapasse,D Horeau-Langlard,F X Blanc,T Lepoivre,M Vourch,S Brouard,R Danger,M Bernard,E Godard,R Valéro,K Maugendre,E Durand,N Yeremenko,A Foureau,J Le Pavec,G Dauriat,P Pradere,S Feuillet,S Dolidon,D Fabre,E Fadel,O Mercier,S Mussot,D Mitilian,A Girault,L Lamrani,Y Castier,P Mordant,P Cerceau,A Roussel,S Jean-Baptiste,S Boudinet,A Gouel,P Montravers,A Tran-Dinh,S Tanaka,N Zappella,A Snauwert,P Tashk,B Lortat-Jacob,T Goletto,D Mouren,M Salpin,H Mal,A Marceau,J Messika,G Weisenburger,V Bunel,L Genet,S Trigueiros,A Bencherif,Y Costa de Beauregard,R Kessler,P Falcoz,A Olland,O Collange,T Degot,A Dory,S Hirschi,L Kessler,S Ohlmann-Caillard,B Renaud-Picard,A Schuller,J Stauder,A Chapelier,E Sage,C Pricopi,M Glorion,J De Wolf,M Le Guen,V Dumans-Nizard,N Liu,S Jacqmin,J Fessler,M Davignon,A Paternot,C Cerf,A G Si Larbi,J Devaquet,G Tachon,B Zuber,M Neuville,E Cuquemelle,F Parquin,S De Miranda,F Gonin,T Ngo,D Usturoi,D Grenet,A M Hamid,C Picard,A Roux,O Brugière,L Beaumont-Azuar,S Colin de Verdière,B D'Urso,L Temagoult,C Bedoui,A Magnan,Q Marquant,I Schwartz,H Salvator,S Laroche,M Delahousse,Y Hertig,A Jalal Eddine,S Hillaire,F Mellot,A Guth,A L Brun,G Gravel,E Longchampt,J Cohen,M Vasse,E Farfour,E Cardot,E Joly,T Pascreau,I Recoche,A Le Borgne,M Murris-Espin,P Rabinel,L Brouchet,L Crognier,O Mathe,F Legenne,M Barthes,B Vilquin,A-L Costes

DOI: https://doi.org/10.1097/TP.0000000000005175

2024-09-19

Transplantation

Abstract:Background: Circulating extracellular vesicles (EVs) have shown promising results as noninvasive biomarkers for predicting disease outcomes in solid organ transplantation. Because in situ graft cell expression of the tolerogenic molecule HLA-G is associated with acceptance after lung transplantation (LTx), we hypothesized that plasma EV-bound HLA-G (HLA-GEV) levels could predict chronic lung allograft dysfunction (CLAD) development. Methods: We analyzed 78 LTx recipients from the Cohort-for-Lung-Transplantation cohort, all in a stable (STA) state within the first year post-LTx. At 3 y, 41 patients remained STA, and 37 had CLAD (bronchiolitis obliterans syndrome, BOS, [n = 32] or restrictive allograft syndrome [n = 5]). HLA-GEV plasma levels were measured at month 6 (M6) and M12 in 78 patients. CLAD occurrence and graft failure at 3 y post-LTx were assessed according to early HLA-GEV plasma levels. Results: In patients with subsequent BOS, (1) HLA-GEV levels at M12 were significantly lower than those in STA patients (P = 0.013) and (2) also significantly lower than their previous levels at M6 (P = 0.04).A lower incidence of CLAD and BOS and higher graft survival at 3 y were observed in patients with high HLA-GEV plasma levels at M12 (high versus low HLA-GEVs patients [cutoff 21.3 ng/mL]: freedom from CLAD, P = 0.002; freedom from BOS, P < 0.001; and graft survival, P = 0.04, [log-rank]). Furthermore, in multivariate analyses, low HLA-GEV levels at M12 were independently associated with a subsequent risk of CLAD, BOS, and graft failure at 3 y (P = 0.015, P = 0.036, and P = 0.026, respectively [Cox models]). Conclusions: This exploratory study suggests the potential of EV-bound HLA-G plasma levels as a liquid biopsy in predicting CLAD/BOS onset and subsequent graft failure.